Lantheus Holdings, Inc. $LNTH Stock Sold by Reinhart Partners LLC.

Reinhart Partners LLC. lessened its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 24.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,207,900 shares of the medical equipment provider’s stock after selling 391,479 shares during the period. Lantheus comprises 2.9% of Reinhart Partners LLC.’s portfolio, making the stock its 11th largest holding. Reinhart Partners LLC. owned about 1.85% of Lantheus worth $120,222,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Diversified Management Inc. purchased a new position in Lantheus in the 3rd quarter worth approximately $375,000. GAMMA Investing LLC boosted its stake in Lantheus by 3.3% during the 3rd quarter. GAMMA Investing LLC now owns 3,457 shares of the medical equipment provider’s stock valued at $344,000 after purchasing an additional 109 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Lantheus by 122.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 555 shares of the medical equipment provider’s stock worth $55,000 after purchasing an additional 306 shares in the last quarter. Integrated Wealth Concepts LLC increased its holdings in shares of Lantheus by 6.7% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 18,709 shares of the medical equipment provider’s stock worth $2,076,000 after purchasing an additional 1,170 shares in the last quarter. Finally, Baird Financial Group Inc. raised its stake in shares of Lantheus by 25.8% in the second quarter. Baird Financial Group Inc. now owns 29,356 shares of the medical equipment provider’s stock worth $3,257,000 after purchasing an additional 6,013 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LNTH. Citizens Jmp reaffirmed a “market outperform” rating and set a $115.00 price target on shares of Lantheus in a report on Monday, June 29th. Mizuho decreased their target price on Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Wednesday, July 29th. TD Cowen cut shares of Lantheus from a “buy” rating to a “hold” rating and lowered their target price for the company from $110.00 to $102.50 in a research note on Monday, August 3rd. William Blair set a $102.50 target price on shares of Lantheus in a research note on Monday, August 3rd. Finally, Weiss Ratings raised shares of Lantheus from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, September 25th. Four equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, Lantheus currently has an average rating of “Hold” and a consensus target price of $108.11.

Lantheus Trading Up 0.0%

Shares of Lantheus stock opened at $100.15 on Friday. The company’s fifty day simple moving average is $100.49 and its 200-day simple moving average is $96.87. The stock has a market capitalization of $6.54 billion, a PE ratio of 24.19 and a beta of -0.06. Lantheus Holdings, Inc. has a 1-year low of $50.15 and a 1-year high of $111.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping the consensus estimate of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The firm had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. During the same period in the prior year, the business posted $1.57 EPS. Lantheus’s revenue was up 2.7% on a year-over-year basis. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 4.54 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company’s portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging.